|
Endo Pharmaceuticals Holdings |
|
|
220 Lake Drive
Newark, 19702 Denmark
phone:(800) 462-3636
fax:(877) 329-3636
|
|
| Symbol |
ENDP |
| Exchange |
NASDAQ |
| Founded |
1997 |
| Employees |
|
|
|
| www.endo.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Development, sale, marketing of pharmaceuticals |
|
| Management |
| David P. Holveck was appointed President, Chief Executive Officer; Robert J. Cobuzzi Jr., Ph.D Senior Director and then Vice President of Scientific Evaluation; Colleen M. Craven, Vice President, Corporate Compliance & Business Practices; Larry Cunningham, Senior Vice President, Human Resources; Ivan Gergel, M.D., Executive Vice President, Research & Development |
| |
|
|
|
|
|
|
|
| Keywords |
| manage pain, overactive bladder, prostate cancer, postherpetic, neuralgia |
|
|
|
| Description |
|
Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM, a topical patch to relieve the pain of postherpetic neuralgia; Percocet and Percodan tablets for the relief of moderate-to-moderately severe pain; FROVA tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; SANCTURA and its XR version for treatment of overactive bladder; VANTAS for the palliative treatment of advanced prostate cancer; SUPPRELIN LA for the treatment of early onset puberty in children; and VALSTAR for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable medical risks. The company markets its branded pharmaceutical products to physicians in pain management, urology, endocrinology, oncology, neurology, surgery and primary care. |
|
| Products / Services |
The Company has a portfolio of branded products that includes such established brand names as Percocet, Lidoderm, Percodan and Zydone.
|
|
| Market / Customers |
Branded products comprised approximately 76%, 67% and 63% of net sales for 2000, 2001 and 2002, respectively.
|
|
| Strategy |
Through a national dedicated sales force, the Company markets its branded pharmaceutical products to doctors, retail pharmacies and other healthcare professionals throughout the United States.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
